| Authors: |
Douez E; UPR 4301 CBM, CNRS, NMNS department, University of Tours, F-37200 Tours, France; Pharmacy Department, Tours University Hospital, F-37200, France. Electronic address: emmanuel.douez@univ-tours.fr., Joubert N; UMR 1100, CEPR, Team Proteolytic enzymes and their pharmacological targeting in lung diseases, University of Tours, INSERM, F-37032 Tours, France., Gabant G; UPR 4301 CBM, CNRS, MO2VING platform, University of Orleans, 45100 Tours, France., Vidy E; UMR 1100, CEPR, Team Proteolytic enzymes and their pharmacological targeting in lung diseases, University of Tours, INSERM, F-37032 Tours, France., Auvert E; UMR 1100, CEPR, Team Proteolytic enzymes and their pharmacological targeting in lung diseases, University of Tours, INSERM, F-37032 Tours, France., Boursin F; UMR 1282 ISP, Team BioMAP, University of Tours - INRAE, F-37200 Tours, France., Dupeyrol G; UMR 1282 ISP, Team BioMAP, University of Tours - INRAE, F-37200 Tours, France., André V; Pharmacy Department, Tours University Hospital, F-37200, France., Velge Roussel F; UPR 4301 CBM, CNRS, NMNS department, University of Tours, F-37200 Tours, France., Denevault-Sabourin C; UMR 1100, CEPR, Team Proteolytic enzymes and their pharmacological targeting in lung diseases, University of Tours, INSERM, F-37032 Tours, France., Aubrey N; UMR 1282 ISP, Team BioMAP, University of Tours - INRAE, F-37200 Tours, France., Allard-Vannier E; UPR 4301 CBM, CNRS, NMNS department, University of Tours, F-37200 Tours, France. |